美诺立尔治疗低度非霍奇金淋巴瘤的II期研究。一项加拿大国立癌症研究所临床试验组的研究。
A phase II study of menogaril in low-grade non-Hodgkin's lymphoma. An NCI Canada Clinical Trials Group study.
作者信息
Skillings J, Cripps C, Eisenhauer E, Pater J, Verma S, Walde D
机构信息
London Regional Cancer Centre, Ontario, Canada.
出版信息
Invest New Drugs. 1991 Feb;9(1):79-82. doi: 10.1007/BF00194551.
PMID:1827434
Abstract
The NCI Canada Clinical Trials Group conducted a phase II study of menogaril given intravenously every 4 weeks in low-grade non-Hodgkin's lymphoma. Fifteen of 26 eligible patients had had no prior therapy. Partial responses were seen in 9 patients (35%). Toxicity was moderate including myelosuppression, nausea, phlebitis, alopecia, and lethargy. This drug has only modest activity in this potentially responsive group of patients.
摘要
加拿大国立癌症研究所临床试验组开展了一项II期研究，针对低度非霍奇金淋巴瘤患者每4周静脉注射一次美诺立尔。26名符合条件的患者中，15名此前未接受过治疗。9名患者（35%）出现部分缓解。毒性反应为中度，包括骨髓抑制、恶心、静脉炎、脱发和乏力。该药在这类可能有反应的患者群体中活性一般。
Zotero 插件